Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GE Spin-Off Wins US Approval For Prostate Cancer PET Tracer

This article was originally published in Clinica

Executive Summary

Two years after being spun out of GE Healthcare’s PET imaging division, Blue Earth Diagnostics (BED) is poised to take its Axumin molecular imaging agent to the US prostate cancer market following FDA approval.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register